These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39407175)

  • 1. Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status.
    Wei Z; Gong B; Li X; Chen C; Zhao Q
    BMC Cancer; 2024 Oct; 24(1):1279. PubMed ID: 39407175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
    Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
    Simon T; Spitz R; Faldum A; Hero B; Berthold F
    J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
    Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
    J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.
    He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C
    Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
    Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
    Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma.
    Yang L; Li Y; Wei Z; Chang X
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2341-2348. PubMed ID: 29247836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis.
    Wang H; Wang X; Xu L
    Ital J Pediatr; 2023 Oct; 49(1):145. PubMed ID: 37904225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.
    Villamón E; Berbegall AP; Piqueras M; Tadeo I; Castel V; Djos A; Martinsson T; Navarro S; Noguera R
    PLoS One; 2013; 8(1):e53740. PubMed ID: 23341988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
    Spitz R; Hero B; Simon T; Berthold F
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
    Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
    Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
    Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
    Pinto N; Naranjo A; Ding X; Zhang FF; Hibbitts E; Kennedy R; Tibbetts R; Wong-Michalak S; Craig DW; Manojlovic Z; Hogarty MD; Kreissman S; Bagatell R; Irwin MS; Park JR; Asgharzadeh S
    Clin Cancer Res; 2023 Apr; 29(8):1546-1556. PubMed ID: 36749880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.
    Gehring M; Berthold F; Edler L; Schwab M; Amler LC
    Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
    Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
    N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.
    Luttikhuis ME; Powell JE; Rees SA; Genus T; Chughtai S; Ramani P; Mann JR; McConville CM
    Br J Cancer; 2001 Aug; 85(4):531-7. PubMed ID: 11506492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q.
    Simon T; Spitz R; Hero B; Berthold F; Faldum A
    Cancer Lett; 2006 Jun; 237(2):215-22. PubMed ID: 16019135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.